Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience
Ipsen Pharma New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly Performance and safety studies ongoing, with first launches for the new device expected in 2024 A fourth generation Somatuline® Autogel® / Somatuline® Depot device building on Ipsen’s 20 years’ heritage to date PARIS, FRANCE, 16 March